Expert Interviews

Dr. Chandra walks the panel through the systemic therapy toolkit for advanced squamous cell carcinoma, organizing it into three categories.

Justin Love, PA-C, explains how multidisciplinary care and earlier targeted therapy can improve chronic inflammatory skin disease outcomes.

Advances in vitiligo, hidradenitis suppurativa, and hair loss were among the key trends Chantel Hillstead, APRN, said APPs should watch.

Lisa Swanson, MD, discussed strategies for counseling patients on JAK inhibitor safety and where she sees the drug class expanding next in a recent Dermatology Times interview.

At Elevate-Derm, Justin Love, PA-C, explains why planning is essential for successful and meaningful patient discussions.

Oyetewa Asempa, MD, discussed the importance of scalp examination, trichoscopy, and culturally informed communication when evaluating patients with hair loss during a recent Dermatology Times interview

Victoria Garcia Albea, NP, discussed safety monitoring, patient selection, and laboratory screening considerations for oral JAK inhibitors at Elevate-Derm summer 2026

At Elevate Derm, Lisa Swanson, MD, discussed earlier oral JAK inhibitor use for alopecia areata and selecting appropriate patients.

At Elevate-Derm, Justin Love, PA-C, urged clinicians to pair diagnostic expertise with emotional intelligence and thoughtful investigation.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses why epidermolysis bullosa simplex remains a difficult gene therapy target.

Aaron Farberg, MD, discusses how Isoclear aims to deliver isotretinoin directly to the skin through a customizable compounded topical system while avoiding the monitoring requirements associated with oral therapy.

Hurley staging built the field's first common language for HS, but the panel explains why it falls short and what newer scoring tools capture instead.

A decade after the first dedicated therapy arrived, the panel reflects on how far HS recognition and treatment have come, and how far they still need to go.

In the latest episode of Don't Be Rash, host Andrew Krakowski, MD, is joined by Raegan D. Hunt, MD, PhD, to discuss newborn skin barrier development, umbilical cord care, and evidence-based product selection.

Building on the first case, Dr. Patel poses a practical dilemma: when a true multidisciplinary team isn't available in real time, who should a community dermatologist reach out to first, a surgeon, a radiation oncologist, or a medical oncologist?

The panel discusses how to navigate treatment selection when patients have preferences and how to compare the available advanced therapies.

In this episode titled "The Future of Vitiligo Care: Patient Selection, Treatment Access, and the Road Ahead," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD offer a forward-looking discussion on incorporating systemic JAK inhibitors into clinical practice, individualizing patient selection, and ensuring equitable access to emerging therapies.

Psoriatic arthritis often surfaces years after the skin diagnosis, making the dermatology visit a decisive checkpoint. This opening segment weighs risk markers and the structured questioning that surfaces joint disease before damage sets in.

Dr. Patel presents the program's first case: a 78-year-old woman with an enlarging, ulcerated lesion on the right temple and preauricular area, measuring close to five centimeters.

The panel provides a detailed breakdown of how a BTK inhibitor works in CSU and reviews key findings from the pivotal clinical trials

Linda Stein Gold, MD, presents tapinarof cream as a long-term, nonsteroidal option for pediatric atopic dermatitis based on data presented at the 2026 Society for Pediatric Dermatology Annual Meeting.

Systematic review highlights AI-supported triage, nursing education, and workforce strategies for underserved communities

Learn from Adnan Mir, MD, PhD, on how better biopsies and direct lab communication help APPs and dermatopathologists boost pediatric skin diagnoses and outcomes.

Lawrence Eichenfield, MD, presented phase 3 results showing lebrikizumab boosts skin clearance, eases itch, and looks safe for infants through teens with moderate to severe atopic dermatitis.

Pediatric vitiligo care now prioritizes comorbidity screening like thyroid checks and anemia evaluation, mental health support, and new therapies including JAK trials and phototherapy options.

Linda Stein Gold, MD, discusses pooled phase 3 tapinarof cream data across pediatric atopic dermatitis age groups presented at the 2026 Society for Pediatric Dermatology meeting.

Pediatric histiocytosis updates at SPD 2026 reveal BRAF/MEK targets as dermatopathology and biopsy genetics boost accuracy in complex childhood dermatoses.

Nanette Silverberg, MD, shares new pediatric vitiligo guidance, spotlighting facial-first goals, topicals, UVB, and steroid "rescue" strategies for widespread, fast-moving disease.

In the final episode, “Improving Access to Advanced Nonsteroidal Topical Therapies in Inflammatory Dermatoses,” the panelists explored practical strategies for overcoming barriers to advanced nonsteroidal topical therapies and discussed how these treatments are reshaping long-term disease management. Building on the consensus statement addressing affordable access, the expert faculty examine the challenges patients and clinicians face when attempting to obtain newer targeted topical treatments and review resources that may help improve treatment accessibility.

This episode, titled “The Evolving Role of Nonsteroidal Topicals in Inflammatory Dermatoses,” features panelists discussing the efficacy of advanced targeted topical therapies and their growing role in the long-term management of inflammatory skin diseases. Building on previous discussions of safety and tolerability, the expert faculty review evidence supporting both the short-term and long-term effectiveness of nonsteroidal topical treatments across multiple inflammatory dermatoses.